Future treatment strategies of aggressive pituitary tumors

Pituitary

Volumn 12, Issue 3, 2009, Pages 261-264

  Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Pharmacotherapy; Pituitary adenoma; Radiotherapy; Surgery

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; CORTICOTROPIN; CYCLIN D1; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROTEIN INHIBITOR; RETINOIC ACID; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN RECEPTOR 5 ANTAGONIST; UNCLASSIFIED DRUG;

ACROMEGALY; ADRENALECTOMY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CUSHING DISEASE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; DOPAMINE AGONISTS; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 67849093885     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0154-y     Document Type: Article

References (20)

1. Jaquet P, Ouafik L, Saveanu A et al (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84(9):3268-3276. doi: 10.1210/jc.84.9.3268
2. Hofland LJ, van der Hoek J, van Koetsveld PM et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577-1585. doi: 10.1210/jc.2003-031344
3. Chaidarun SS, Swearingen B, Alexander JM (1998) Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab 83(9):3308-3315. doi: 10.1210/ jc.83.9.3308
4. Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER (1999) Estrogen receptors in prolactinomas: A clinico-pathological study. Pituitary 1(2):91-98. doi: 10.1023/A:1009903603495
5. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485-534. doi: 10.1210/ er.2005-9998
6. van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754-1759. doi: 10.1016/S0140-6736(01)06844-1
7. Ferrante E, Pellegrini C, Bondioni S et al (2006) Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 13(3):955-962. doi: 10.1677/ erc.1.01191
8. Sharma K, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10(12):1688-1696. doi: 10.1210/ me.10.12.1688
9. Hofland LJ (2008) Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol 286(1-2):199-205. doi: 10.1016/ j.mce.2007.10.015
10. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A (1999) Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22(11):860-865
11. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH (1975) Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. J Clin Endocrinol Metab 40(6):1125-1127
12. Lamberts SW, Uitterlinden P, Klijn JM (1989) The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 120(6):760-766
13. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G (1990) Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13(3):257-261
14. Hofland LJ, van der Hoek J, Feelders R et al (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645-654. doi: 10.1530/eje.1.01876
15. Batista DL, Zhang X, Gejman R et al (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91(11):4482-4488. doi: 10.1210/jc.2006-1245
16. de Bruin C, Pereira AM, Feelders R et al (2008) Co-expression of dopamine and somatostatin receptor subtypes in human corticotroph adenomas in ENDO. San Francisco, USA
17. Paez-Pereda M, Kovalovsky D, Hopfner U et al (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108(8):1123-1131
18. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13(2):220-240. doi: 10.1210/ er.13.2.220
19. de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW et al (1992) Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 75(5):1310-1317. doi: 10.1210/jc.75.5.1310
20. Florio T, Barbieri F, Spaziante R et al (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study. Endocr Relat Cancer 15(2):583-596. doi: 10.1677/ERC-07-0271